The Clinical Significance of Fibrin Monomers

Majed A. Refaai1 Paul Riley2 Tatsiana Mardovina2 Phoenix D. Bell1

1Department of Pathology and Laboratory Medicine, Thrombosis and Hemostasis Research Laboratory, University of Rochester Medical Center, University of Rochester, Rochester, New York, United States
2Diagnostica Stago, Inc., Parsippany, New Jersey, United States

Address for correspondence Majed A. Refaai, MD, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue Box no. 608, Rochester, NY 14642, United States (e-mail: m.refaai@rochester.edu).


Abstract

Introduction  Fibrin monomer (FM) concentrations reflect pro-thrombin activity and have the potential to predict thrombotic events relatively earlier than other haemostatic markers. Most often, FM are compared with D-dimer (DD) as increased DD have been documented in disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT) and pulmonary embolism. Although DD have a high sensitivity and negative predictive value, their specificity is much lower depending on the assay chosen, clinical pre-test probability and patient condition. There are limited reports investigating the utility of FM in hyper-coagulable patients.

Methods  We performed a literature search of FM concentrations in hyper-coagulable patients including those with DIC, acute ischaemic stroke, atrial fibrillation, acute myocardial infarction, venous thromboembolism (VTE) and cancer, as well as those who are pregnant or undergoing surgery.

Results  FM were increased in patients with DIC and those with malignancy. In contrast, detection of VTE or post-operative DVT development is likely enhanced using both FM and DD concentrations. Similarly, measuring FM concentrations with other biomarker levels may be more beneficial in patients suffering an acute myocardial infarction or acute ischaemic stroke. Lastly, FM concentrations vary substantially throughout pregnancy with no definitive role of FM as of yet.

Conclusion  Utilizing FM concentrations to assess hyper-coagulable patients seems promising; however, there are limitations including variations in FM cut-off values, the effect of patient medications and the timing of FM measurement relative to an acute event. Thus, further investigation is required before a true advantage for FM as a haemostatic marker can be established.

Keywords

► thrombosis
► D-dimers
► venous thromboembolic event
► fibrin split products
► hyper-coagulation

Introduction

Haemostasis is a complex physiological process of blood clot formation at the site of vessel injury to control bleeding. The haemostatic response is quick, localized and well regulated. During haemostasis, three steps occur simultaneously in a rapid order, including vasoconstriction, generation of a platelet plug (primary haemostasis) and activation of the coagulation process (secondary haemostasis), leading to fibrin clot formation.1 This insoluble fibrin forms a mesh incorporated into and around the platelet plug to strengthen and stabilize the clot.

Different laboratory tests can be used to monitor haemostatic status, including pro-thrombin time, activated partial thromboplastin time, fibrinogen, factor activity, platelet count and function, fibrin degradation products (FDPs; also known as fibrin split products) and D-dimers (DD). Historically, DD have been used as one of the indicators of thrombotic states such as venous thromboembolism (VTE).
Thrombin, which is a key protease of the coagulation system, cleaves fibrinopeptides A and B from fibrinogen, creating soluble fibrin monomers (SFM). These SFMs can combine with fibrinogen and form non-covalently associated soluble fibrin monomer complexes (SFMCs). In the final steps, SFMCs polymerize, via factor XIIIa (FXIIIa) crosslinking, and a thrombus is formed (Fig. 1). Since SFM concentration reflects thrombin activity, and their levels can be detected earlier than DD, SFM can be used as an alternative for assessing thrombosis. The role of SFM in various thrombotic states is relatively supported in the literature; however, there is no current comprehensive review of the clinical significance of SFM. Of note, for the purposes of biochemistry and laboratory measurement, SFM, FM, SF, FMC, and SFMC are indistinguishable from one another, though all abbreviations are used in different literature over the years. For simplicity, FM abbreviation will be used for all of these molecules in this review.

**Methods**

A literature search was conducted using the PubMed database with search terms including “fibrin monomers” or “fibrin monomer complexes” in general and with different hyper-coagulable states. A detailed summary of available studies was provided by M.A.R. and P.D.B. The list of literature was then reviewed, analysed and evaluated by all authors for inclusion in this article. Studies were deemed appropriate for this review if the relationship between FM and any hyper-coagulable state was appropriately examined, analysed and/or evaluated.

**Fibrin Monomer Concentration and Disseminated Intravascular Coagulation**

The diagnosis of disseminated intravascular coagulation (DIC) relies upon the patient’s clinical picture and specific laboratory findings. DIC is often suspected in patients with sepsis, malignancy or unexplained bleeding/thrombosis. FM could potentially be used as an independent predictor of DIC. Wada et al. analysed FM concentrations in 149 suspected DIC patients categorized into three groups: patients with non-DIC ($n = 75$), with DIC ($n = 46$) and patients with pre-DIC ($n = 28$) who developed DIC within 1 week after clinical progression. The presentation FM were significantly higher in the DIC group (mean ± standard deviation [SD]: $363 ± 314 \mu g/mL$) versus the pre-DIC group ($181 ± 132 \mu g/mL, p < 0.01$). Nevertheless, pre-DIC patients also showed significantly higher FM versus patients with non-DIC ($52.5 ± 50.4 \mu g/mL, p < 0.01$). When DIC patients were treated with gabexate mesylate (FOY), FM significantly decreased to $244 ± 340 \mu g/mL (p < 0.05)$. Thus, FM could be used as a marker to help determine DIC severity.

Similarly, Singh et al. evaluated the utility of FM and DD in 70 patients with suspected DIC. Patients were separated into three groups: overt DIC ($n = 32$), non-overt DIC ($n = 24$) and non-DIC ($n = 14$). The median DD was significantly different in the overt DIC group compared with the non-overt and non-DIC groups.

![Fig. 1](image-url) Formation of soluble fibrin monomer complexes. 4
Table 1 Outcome summary of the included fibrin monomer studies grouped per the hyper-coagulability condition

<table>
<thead>
<tr>
<th>Authors</th>
<th>Type of study</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FM and disseminated intravascular coagulation (DIC)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dempfle et al$^{13}$</td>
<td>Prospective</td>
<td>FM improves the prognostic performance of the overt DIC score ($N = 359$)</td>
</tr>
<tr>
<td>Wada et al$^{17}$</td>
<td>Retrospective</td>
<td>FM could be used to help distinguish patients with non-DIC, pre-DIC and DIC ($N = 149$)</td>
</tr>
<tr>
<td>Singh et al$^{8}$</td>
<td>Prospective</td>
<td>FM are superior to DD in detecting DIC severity ($N = 70$)</td>
</tr>
<tr>
<td>Selim et al$^{9}$</td>
<td>Prospective</td>
<td>FM could help identify septic neonates at risk of developing DIC ($N = 23$)</td>
</tr>
<tr>
<td>Park et al$^{16}$</td>
<td>Retrospective</td>
<td>FM is comparable to DD at predicting DIC ($N = 139$)</td>
</tr>
<tr>
<td>Okamoto et al$^{12}$</td>
<td>Prospective</td>
<td>No appropriate cut-off value for FM exists to distinguish patients with ‘pre-DIC’ from those ‘without DIC’ ($N = 613$)</td>
</tr>
<tr>
<td><strong>FM and venous thromboembolism (VTE)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dopsaj et al$^{17}$</td>
<td>Retrospective</td>
<td>Using both DD and FM for DVT exclusion is superior to using DD alone ($N = 121$)</td>
</tr>
<tr>
<td>Reber et al$^{19}$</td>
<td>Retrospective</td>
<td>FM may be a useful marker in patients with clinically suspected PE ($N = 426$)</td>
</tr>
<tr>
<td>Schutgens et al$^{16}$</td>
<td>Retrospective</td>
<td>FM in patients with a high PTP of DVT may decrease the need for serial compression ultrasounds ($N = 464$)</td>
</tr>
<tr>
<td>Elias et al$^{18}$</td>
<td>Prospective</td>
<td>FM is not useful in detecting small DVTs ($N = 231$)</td>
</tr>
<tr>
<td><strong>FM and malignancy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beer et al$^{13}$</td>
<td>Prospective</td>
<td>FM can be used to risk stratify cancer patients ($N = 268$)</td>
</tr>
<tr>
<td>Biggerstaff et al$^{11}$</td>
<td>Basic science</td>
<td>FM enhances platelet adhesion to tumour cells and may contribute to metastasis</td>
</tr>
<tr>
<td>Seeholzer et al$^{22}$</td>
<td>Retrospective</td>
<td>FM may be associated with tumour growth ($N = 25$)</td>
</tr>
<tr>
<td>Tsimafeyeu et al$^{24}$</td>
<td>Retrospective</td>
<td>FM may be used to predict chemotherapy response and survival in patients with metastatic renal cell carcinoma ($N = 289$)</td>
</tr>
<tr>
<td><strong>FM and acute ischaemic stroke (AIS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hirano et al$^{27}$</td>
<td>Retrospective</td>
<td>FM can be used to discriminate patients with cardioembolic versus non-cardioembolic stroke ($N = 69$)</td>
</tr>
<tr>
<td>Tamura et al$^{32}$</td>
<td>Retrospective</td>
<td>Increased FM in AIS patients may contribute to the development of future cerebrovascular events ($N = 113$)</td>
</tr>
<tr>
<td>Okuayama et al$^{26}$</td>
<td>Retrospective</td>
<td>FM may be used to predict the presence of intra-cardiac emboli, or a hyper-coagulable state, in AIS patients ($N = 204$)</td>
</tr>
<tr>
<td>Fassbender et al$^{24}$</td>
<td>Retrospective</td>
<td>AIS patients had increased FM levels; however, levels were even higher after rtPA administration ($N = 44$)</td>
</tr>
<tr>
<td><strong>FM and atrial fibrillation (AF)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sato et al$^{10}$</td>
<td>Retrospective</td>
<td>The interaction between vWF and fibrin may promote thrombosis in AF ($N = 183$)</td>
</tr>
<tr>
<td>Rivera-Caravaca et al$^{31}$</td>
<td>Retrospective</td>
<td>In AF, unclear whether FM enhance risk stratification ($N = 1,226$)</td>
</tr>
<tr>
<td>Sadanaga and Mitamura$^{3}$</td>
<td>Retrospective</td>
<td>FM do not predict future thromboembolic events in patients with AF ($N = 122$)</td>
</tr>
<tr>
<td>Tóth et al$^{32}$</td>
<td>Retrospective</td>
<td>No differences in FM were seen in patients with AF versus without AF ($N = 24$)</td>
</tr>
<tr>
<td><strong>FM and acute myocardial infarction (AMI)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ieko et al$^{5}$</td>
<td>Retrospective</td>
<td>FM is a predictor of early coronary thrombus development in the first 24 hours of AMI ($N = 47$)</td>
</tr>
<tr>
<td>Elged et al$^{34}$</td>
<td>Retrospective</td>
<td>FM could enhance AMI detection in patients with chest pain ($N = 75$)</td>
</tr>
<tr>
<td>Kontny et al$^{33}$</td>
<td>Retrospective</td>
<td>FM could be used to predict mortality following AMI ($N = 293$)</td>
</tr>
<tr>
<td>Brugger-Anderson et al$^{35}$</td>
<td>Retrospective</td>
<td>FM is not a good prognostic marker for AMI as it is influenced by PCI and tenecteplase treatments ($N = 38$)</td>
</tr>
<tr>
<td><strong>FM and pregnancy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Wersch and Ubachs$^{2}$</td>
<td>Retrospective</td>
<td>FM are elevated throughout pregnancy and may be used as a baseline comparison for high-risk pregnancies associated with a hyper-coagulable state ($N = 56$)</td>
</tr>
<tr>
<td>Grossman et al$^{18}$</td>
<td>Prospective</td>
<td>FM may enhance the detection of VTE in pregnancy ($N = 2,870$)</td>
</tr>
<tr>
<td>Onishi et al$^{36}$</td>
<td>Retrospective</td>
<td>FM could be used to monitor hyper-coagulability in pregnancy ($N = 215$)</td>
</tr>
<tr>
<td>Joly et al$^{11}$</td>
<td>Retrospective</td>
<td>FM are not a useful marker for hyper-coagulability throughout pregnancy, as their levels fluctuate ($N = 101$)</td>
</tr>
<tr>
<td><strong>FM and surgery</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vogel et al$^{19}$</td>
<td>Retrospective</td>
<td>FM is a potential early marker for DVT during the surgical period ($N = 129$)</td>
</tr>
<tr>
<td>Hasegawa et al$^{40}$</td>
<td>Retrospective</td>
<td>FM may help diagnose subclinical VTE or help predict post-op VTE ($N = 326$)</td>
</tr>
<tr>
<td>Koch et al$^{14}$</td>
<td>Retrospective</td>
<td>FM in surgical patients could be used as an indication for anti-coagulation therapy ($N = 123$)</td>
</tr>
<tr>
<td>Yoshisaka et al$^{42}$</td>
<td>Retrospective</td>
<td>Elevated FM on POD1 in spinal surgery patients may indicate future DVT development ($N = 72$)</td>
</tr>
<tr>
<td>Watanabe et al$^{43}$</td>
<td>Retrospective</td>
<td>FM may be an early predictor of post-op thrombosis development in spinal surgery patients ($N = 56$)</td>
</tr>
<tr>
<td>Mitani et al$^{41}$</td>
<td>Retrospective</td>
<td>FM may be useful for early DVT diagnosis ($N = 50$)</td>
</tr>
</tbody>
</table>

Abbreviations: DD, D-dimer; DVT, deep vein thrombosis; FM, fibrin monomer; PCI, percutaneous coronary intervention; PE, pulmonary embolism; POD1, post-op day 1; PTP, pre-test probability; rtPA, recombinant tissue plasminogen activator; vWF, von Willebrand factor.

Note: Studies are listed in order of clinical relevance.
non-DIC groups (6.55 vs. 2.84 and 2.35 μg/mL; \( p = 0.001 \) and \( p = 0.003 \), respectively). However, the median DD was not significantly different between the non-overt and non-DIC groups (\( p = 0.17 \)). In comparison, the mean FM concentration was significantly different between patients with overt DIC, non-overt DIC and non-DIC (55.6 vs. 9.65 and 5.98 μg/mL; \( p < 0.001 \) by chi-square). Furthermore, multivariate analysis showed only FM could independently differentiate patients with overt DIC from non-DIC (odds ratio [OR], 43.4; confidence interval [CI], 4.61–406.68; \( p = 0.001 \)), as well as patients with non-overt DIC from non-DIC (OR, 18.3; CI, 3.45–97.19; \( p = 0.001 \)). Ultimately, the authors proposed that FMs are superior to DD in detecting DIC severity.

Selim et al. evaluated FM concentrations in healthy (n = 10) versus septic neonates (n = 13), of which, 10 of 13 were diagnosed with DIC. FMs were significantly higher in septic neonates without DIC versus healthy neonates (33.69 ± 11.85 vs. 24.5 ± 6.09 μg/mL, \( p < 0.05 \)). FMs were also significantly higher in septic neonates with DIC versus septic neonates without DIC (73.2 ± 31.55 vs. 33.69 ± 11.85 μg/mL; \( p < 0.001 \)). The receiver operating characteristic (ROC) curve analysis established the FM cut-off at 48.5 μg/mL, with the sensitivity for diagnosing DIC of 100%, specificity of 95% and overall accuracy of 97.5%. The authors suggested FM concentrations could help identify septic neonates at risk of developing DIC.

FMs were also shown to be a better predictor of mortality in early-stage DIC in critically ill adult patients. Utilizing two different DD assays, MDA (bioMérieux Inc., Durham, North Carolina, United States) and TINAquant (Roche Diagnostics, Mannheim, Germany), and latex FM assay (Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan), Dempfle et al. compared the use of DD and FM as the fibrin-related marker in the International Society of Thrombosis and Haemostasis overt DIC score. These analytes were measured in 359 intensive care unit (ICU) patients over 6 months and compared with mortality. In patients with overt DIC on day 1 of ICU admission, the calculated mortality rate using MDA DD assay was 35.5% and TINAquant DD assay was 39.3% (\( p = 0.032 \) and \( p = 0.012 \), respectively) versus 50% using FM (\( p < 0.001 \)). Comparing day 1 results of patients without DIC and patients with DIC, the 28-day mortality rate was 15.6% versus 35.5% (\( p = 0.011 \)) for MDA DD assay, 15.5% versus 39.3% (\( p = 0.004 \)) for TINAquant DD assay and 14.0% versus 50.5% (\( p < 0.001 \)) for FM. This group suggests FM may improve the prognostic power of the overt DIC score.

In contrast, other groups illustrated that FM could not be used alone to predict the different stages of DIC. Okamoto et al. conducted a study of 613 patients with suspected DIC and separated them into three groups based on DIC severity. There were 368 patients without DIC, 211 with DIC and 34 with pre-DIC (who would eventually develop DIC within 7 days of admission). As expected, FM concentrations were significantly higher in patients with pre-DIC versus DIC without DIC (median [range]: 56.1 [12.1–151] vs. 14.1 [6.2–91.8] μg/mL, \( p < 0.05 \)). However, comparing patients with DIC versus patients without DIC, ROC analysis showed a sensitivity of 91.9%, specificity of 41.9% and OR of 8.199 (4.987–13.48; \( p < 0.001 \)). Whereas comparing pre-DIC patients to patients without DIC, sensitivity decreased to 80%, specificity to 41% and OR to 2.780 (1.144–6.754; \( p < 0.05 \)). Thus, no appropriate FM cut-off value can be established to distinguish DIC severity. Park et al. evaluated FM and DD in 139 patients with DIC-associated diseases and separated them into three groups: group 1: non-DIC (n = 43), group 2: non-overt DIC (n = 80) and group 3: overt DIC (n = 16). The median FM and DD were significantly different between each group (\( p < 0.001 \), each). Additionally, there was significant correlation between FM and DD versus DIC score (FM: \( r = 0.3975 \), \( p < 0.001 \); DD: \( r = 0.4280 \), \( p < 0.001 \)). FM and DD were significantly correlated in non-DIC and non-overt DIC patients (\( r = 0.5556 \), \( p < 0.001 \)). However, no correlation was seen between FM and DD with overt DIC patients (\( p = 0.104 \)). ROC analysis also showed an equal effectiveness of FM and DD in diagnosing DIC. They concluded that FMs are comparable to DD at predicting DIC.

As shown, these studies demonstrated significant increases of FM in DIC patients. However, it is unclear whether FM cut-off values exist for stratifying patients based on DIC severity.

**Fibrin Monomer Concentration and Venous Thromboembolism**

There is significant morbidity and mortality associated with the development of VTE; nonetheless, diagnosing deep venous thrombosis (DVT) or pulmonary embolism (PE) continues to be a challenge and confirmation relies upon a multimodal approach including calculation of a clinical pre-test probability (PTP) score, DD concentrations, serial compression ultrasonographies (CUS) and a computed tomography pulmonary angiography. Schutgens et al. evaluated the utility of DD and FM in 446 outpatients with suspected DVT. Patients with high PTP receiving a single CUS with a normal DD or FM had a slightly higher negative predictive value (NPV) versus patients receiving serial CUS (100 vs. 98%). Replacing the first CUS by DD and FM decreased the NPV significantly. In patients with any PTP score, the serial CUS NPV was 97%. Replacing the second CUS in this group of patients by a normal FM value showed similar NPV (97%). They concluded that, when used alone, FMs are not as useful as the DD tests in excluding DVT. However, using FM and DD in patients with a high PTP of DVT could decrease the need for serial CUS.

Dopsaj et al. compared FM and DD concentrations in 96 patients with suspected DVT, grouped as DVT likely (n = 17) and DVT unlikely (n = 79). Using three different DD assays, the ROC analysis demonstrated higher area under the curve (AUC) in all of the three assays. However, AUC significantly increased when FM was included with DD (\( p < 0.05 \)). Thus, using both DD and FM is superior to DD alone in excluding DVT. Nevertheless, in another study done by Elias et al., three different FM assays and one DD assay were used to evaluate patients with clinically suspected DVT (n = 231). Patients were categorized into three groups: confirmed DVT, DVT ≥4 cm and proximal DVT. The ROC analysis revealed higher AUC values for the DD assay 0.77 (0.72–0.82) versus those of the FM assays (range: 0.58–0.69; \( p < 0.05 \)). The
authors concluded that DD is better than FM for detecting DVT in patients with a small DVT.

Reber et al. assessed FM and DD concentrations in 127 patients diagnosed with PE out of 426 patients with clinically suspected PE. Using a FM cut-off of 3 µg/mL, the sensitivity was 100% (95% CI: 97.1–100), specificity was 32.8% (95% CI: 25.7–38.1) and NPV was 100% (95% CI: 96.3–100). Increasing the cut-off to 4 µg/mL, the sensitivity was 98.4% (95% CI: 94.4–99.2), specificity was 39.1% (95% CI: 33.6–44.7) and NPV was 98.3% (CI: 94.1–99.8). The authors determined that FM could exclude PE in 23% of patients with the lower cut-off and 27% with the higher cut-off, ultimately suggesting FM may be useful in patients with clinically suspected PE.

There are limited studies assessing the utility of FM in early detection of DVT or PE; however, the preceding studies suggest FM could enhance current methods used to detect VTE.

**Fibrin Monomer Concentration and Malignancy**

Patients with an undiagnosed malignancy often present with an acute hyper-coagulable state. There is insufficient literature investigating the role of FM in early detection of cancer-induced hyper-coagulability. Beer et al. measured haemostatic factors in 268 cancer outpatients, of which 72 were in complete remission, 55 had limited disease (regional lymph node metastasis) and 141 had extensive disease (distant metastasis). In addition to FM, DD, thrombin–anti-thrombin complex (TAT), pro-thrombin fragments 1 + 2 (F1+2) and fibrinopeptide A were measured in all patients. All tests were significantly elevated in patients with active disease versus patients in remission (p < 0.001, each) including FM (mean ± SD, 26.6 ± 83.6 vs. 4.9 ± 8.9 µg/mL). When analysing patients with active disease, all of these tests were significantly higher in the group that died versus the group that survived (p = 0.016, each). Since FMs were higher in patients with active malignancy and in those who died (40.3 ± 23.0) versus patients who survived (18.5 ± 9.6, p < 0.001), they concluded FM could be used to risk stratify cancer patients.

To study the effect of FM on platelet aggregation and tumour cells, fluorescently labelled platelets were added to human amelanotic malignant melanoma cells. Using confocal laser scanning microscopy, Biggerstaff et al. observed platelet aggregation after exposure to the malignant cells over 30 minutes. Limited binding of platelets to the tumour cells was apparent. Pre-treating the tumour cells with fibrinogen did not reflect a difference in platelet binding. In contrast, pre-treating tumour cells with FM demonstrated a drastic increase in platelet binding. They proposed FM enhance platelet adhesion to tumour cells and may possibly contribute to metastasis.

Seeholzer et al. evaluated FM and response rates in 25 patients with advanced breast cancer given docetaxel and enoxaparin in a phase II clinical trial. FMs were significantly decreased in patients with partial remission (p = 0.037) and showed a trend towards significance in those with stable disease (p = 0.08), yet no significant difference was seen in patients with progressive disease (p = 0.48). The authors suggested that FM may be associated with tumour growth.

Tsimafeyeu et al. retrospectively evaluated 289 patients with metastatic renal cell carcinoma (MRCC) who had never received prior treatment. Patients were categorized into low, intermediate and high ‘extent of hyper-coagulability’ based upon their fibrinogen, DD and FM levels. Patients with a greater degree of hyper-coagulability had significantly higher number of metastatic sites (≥ 4 vs. 1–3; p = 0.02). On univariate analysis, hyper-coagulable patients also had significantly decreased survival compared with patients with normal coagulability (median survival: 8.9 vs. 16.3 months, p = 0.001). Hyper-coagulability remained an independent predictor of survival on multivariate analysis (hazard ratio [HR], 1.63; 95% CI: 1.5–1.76). They concluded that patients with MRCC are hyper-coagulable, and those with greater degrees of hyper-coagulability have decreased overall survival.

As detailed by the above studies, cancer patients are hyper-coagulable and have increased FM levels. These levels are higher in patients with active disease versus those in remission, which may be due to FM-mediated interactions between platelets and tumour cells.

**Fibrin Monomer Concentration and Stroke**

Current practice for stroke diagnosis utilizes a patient’s clinical presentation, head imaging, electrocardiograms and cardiac enzymes. Few studies have evaluated the application of FM in stroke patients, which involves measurement of various haemostatic factors before, during and after an acute cerebrovascular accident (CVA). Along with DD, TAT and F1+2, FMs were measured in acute ischaemic stroke patients (n = 44) who presented 2 to 6 hours after symptom onset and received recombinant tissue plasminogen activator (rtPA) and heparin. In comparison to age- and risk factor-matched control subjects, higher FMs were detected at 1, 3 and 5 hours after heparin therapy (p < 0.01). Levels were also compared with stroke patients treated only with heparin (n = 21) and FMs were significantly higher after rtPA therapy versus heparin therapy alone (p < 0.05). Thus, FM concentrations are elevated in patients with acute ischaemic stroke but not as significantly versus following rtPA therapy.

To identify a possible marker for use in predicting stroke recurrence, Tamura et al. measured FM, C-reactive protein (CRP), plasminogen α2 inhibitor complex (PIC), DD and FDP in 113 acute stroke patients following their initial cerebrovascular event. They found patients with a recurrent stroke episode had significantly higher concentrations of FM, CRP, PIC and DD versus patients without an event (p < 0.05, each). A significant linear relationship between FM and these markers was detected (CRP: R = 0.310, p = 0.004; PIC: R = 0.654, p < 0.001; DD: R = 0.724, p < 0.001; FDP: R = 0.724, p < 0.001). On multivariate analysis, only increased FM were significantly associated with the development of a future event and/or death (HR, 1.516 per -SD increase; 95% CI: 1.042–2.180; p = 0.036). They suggested elevated FM in acute ischaemic stroke patients indicate hyper-coagulability, which may contribute to the development of a future cerebrovascular event.

In another study, significantly higher FMs were detected in acute ischaemic stroke patients who developed a left atrial appendage (LAA) thrombus within 7 days of stroke (n = 24) versus patients without thrombus development (n = 180) (FM: 88 ± 52 vs. 14 ± 9 µg/mL, p < 0.001). Additionally,
FM levels were an independent predictor for LAA thrombus development (risk ratio, 2.975 per 10 µg/mL increase; 95% CI: 1.114–4.820, \( p = 0.021 \)). They concluded that FM may be used to predict the development of intra-cardiac emboli in acute ischaemic stroke patients.

Haemostatic markers were measured on days 1, 2, 3 and 7 of hospitalization of acute cerebral infarction patients (\( n = 69 \)).\(^{27} \) Patients were sub-grouped based on stroke type, cardioembolic versus non-cardioembolic stroke. In addition to DD and FDP, FMs were significantly higher in patients with cardioembolic stroke on day 1 of hospitalization (\( 37.5 \pm 68.9 \) vs. \( 6.6 \pm 8.6 \) µg/mL, \( p < 0.01 \)). Hirano et al\(^{27} \) summarized that biomarkers, such as FM, can be used to discriminate patients with cardioembolic versus non-cardioembolic stroke in the early stages.

Overall, these studies provide convincing evidence that FM elevations are indicative of a hyper-coagulable state during acute ischaemic stroke; however, they do not indicate their future utility in early detection of CVAs.

Fibrin Monomer Concentration and Atrial Fibrillation

Patients with atrial fibrillation (AF) are hyper-coagulable and at higher risk for developing an acute embolic stroke. Clinicians evaluate this stroke risk using the CHA\(_2\)DS\(_2\)-VASC score (congestive heart failure [CHF], hypertension, age \( \geq 75 \) years, diabetes, prior stroke/transient ischaemic attack, vascular disease, age 65–74 years, sex category)\(^{28} \); however, no coagulopathic markers are incorporated into this algorithm.

Sato et al\(^{29} \) examined haemostatic marker levels (von Willebrand factor [vWF], DD, PIC, TAT, F\(_{1+2}\) and FM) in 183 patients with acute ischaemic stroke and compared these levels (at admission) between patients with and without AF. Patients were categorized into mild, moderate and severe stroke severity based on the National Institutes of Health Stroke Scale.\(^{30} \) FM along with vWF, DD, PIC and TAT were significantly increased in AF patients compared with levels in non-AF patients (FM: 23.19 vs. 11.83 µg/mL, \( p = 0.043 \)); however, in AF patients, only PIC (\( r = 0.551 \); \( p = 0.002 \)) and FM (\( r = 0.449 \); \( p = 0.003 \)) levels were significantly correlated with vWF. They concluded that vWF levels may reflect a hyper-coagulable state in patients with AF and, although less clear, the correlation between vWF and FM may suggest an interaction between vWF and fibrin which may promote thrombosis in AF patients.

In a different study, 1,226 patients with AF taking a vitamin K antagonist (for at least 6 months) were followed for 6.5 years and the number of ischaemic strokes, adverse cardiovascular events (heart failure, stroke, cardiovascular death, vascular death, any cardiovascular death) were reported.\(^{31} \) FMs were significantly higher in patients who suffered a composite cardiovascular event (5.3 vs. 4.7 µg/mL, \( p = 0.007 \)) or a cardiovascular death (6.2 vs. 4.8 µg/mL, \( p = 0.032 \)). Multivariate analysis showed patients with high FM levels (> 12 µg/mL) had an increased risk for cardiovascular events (HR, 1.72; 95% CI: 1.31–2.26), cardiovascular mortality (HR, 2.16; 95% CI: 1.30–3.57) and all-cause mortality (HR, 1.26; 95% CI, 1.03–1.55). FM did not correlate to the CHA\(_2\)DS\(_2\)-VASC score (rho = 0.002, \( p = 0.938 \)), and when evaluated concomitantly with the CHA\(_2\)DS\(_2\)-VASC score, there was no difference in their predictive performance. They concluded that, for AF patients, it is unclear whether FM enhances risk stratification.

Sadanaga and Mitamura\(^{3} \) conducted a post hoc analysis of a reported cohort of patients with AF. In the first group, they evaluated FM levels in 21 patients with AF before and after (> 4 weeks) warfarin administration. In the second group, they evaluated FM levels in 101 AF patients on long-term warfarin. Using a FM cut-off level of 3 µg/mL, FM levels in the first group significantly decreased after warfarin administration from 3.6 to 1.5 µg/mL (\( p < 0.01 \)). In contrast, in the second group, 9 (9%) patients experienced a thromboembolic event; ROC analysis did not result in an optimal FM cut-off level to predict these events (\( p = 0.68 \), AUC = 0.48).

Additionally, when the FM cut-off level was set to 3 µg/mL, 26 (26%) patients had elevated FM (> 3 µg/mL) and there were 2 thromboembolic events. FM levels were not associated with the development of future thromboembolic events (\( p = 0.63 \) by log-rank test). They concluded that there is no utility for FM in the prediction of future thromboembolic events in patients with AF.

Töth et al\(^{32} \) evaluated haemostatic markers (fibrinogen, FVIII, FXIII activity, vWF antigen, TAT, FM, plasminogen, α\(_2\)-plasmin inhibitor, plasmin–α\(_2\)-antiplasmin complex [PAP], PAI1 activity and DD) in 24 patients with AF and a control group of 14 patients with supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Levels were measured in blood samples taken from the femoral vein, left atrium and LAA before the ablation procedure. They found that FVIII and vWF were significantly elevated in the femoral vein and left atrium samples of AF patients versus controls. TAT, FM, PAP and DD were significantly elevated in both groups. They concluded that there is no difference between haemostatic and fibrinolytic markers in AF and non-AF groups and that the recorded elevations were actually due to endothelial damage from catheterization.

In general, these studies represent competing views on the role of FM in the assessment of patients with AF. Some believe that FM may assist in cardiovascular risk stratification or that FM may lead to hyper-coagulability in AF patients due to interactions with vWF, while others state that FM levels have no utility in the assessment of thrombosis in AF patients.

Fibrin Monomer Concentration and Acute Myocardial Infarction

Few reports exist investigating the relationship of DD and FM to acute myocardial infarction (AMI) development. FMs were examined in long-term outcomes of patients who developed an AMI (\( n = 293 \)) while anti-coagulated with dalteparin (Fragmin).\(^{33} \) FMs were significantly higher in patients with a mortality outcome 2 days post-MI versus surviving patients (median [range]: 1.8 [\(< 0.01–73.1\) vs. 0.4 [\(< 0.01–103.5\)] µg/mL, \( p < 0.001 \)). Additionally, significantly higher FMs were seen in patients with CHF, not on dalteparin or not on thrombolytic therapy (\( p = 0.016 \), each). After accounting for these variables, the relationship between FM and mortality remained significant (OR, 1.9, 95% CI: 1.04–3.5, \( p = 0.04 \)). Kontry et al\(^{33} \) concluded that the use of FM, in combination with other risk factors, could be used to predict mortality following AMI.
Additionally, DD and FM were significantly increased in AMI patients during the first 24 hours (n = 47) as compared with >24-hour period (FM: 14.81 ± 25.87 vs. 1.15 ± 0.84 μg/mL, p = 0.003). This is in contrast to the concentrations of serum creatine kinase MB (CKMB), creatine kinase and troponin T, which were higher after 24 hours rather than within the first 24 hours. ROC analysis demonstrated FMs were superior to DD and CKMB within the first 24 hours of AMI onset. Thus, the authors concluded that measuring FM was a better predictor of early coronary thrombus development than other biomarkers. Similarly, Elged et al.34 explored the impact of FM on diagnosing AMI in conjunction with cardiac troponins. When comparing patients with AMI (n = 35) versus those with chest pain but no AMI (n = 40), FM enhanced diagnostic accuracy when used in conjunction with troponins (AUC, 0.985; specificity, 97.5%; positive predictive value [PPV], 97%) compared with when soluble cardiac troponin I (s-cTnI) (AUC, 0.903; specificity, 97.5%; positive predictive value (PPV), 84.2%) or FM (AUC, 0.946; specificity, 90%; PPV, 89.5%) was used alone. Thus, adding FM to an AMI workup, in parallel with s-cTnI, could enhance AMI diagnosis.

DD and FM concentrations were measured in patients (n = 38) admitted with a ST-elevation myocardial infarction (PCI: n = 20) or thrombolytic administration (n = 18).35 In addition to DD, FM increased significantly after tenecteplase (mean [range]: 3.25 [0.8–14.5] vs. 1.34 [1.6–7.44] μg/mL, p < 0.001). However, only FM significantly increased after PCI (4.55 [0.5–396] vs. 3.25 [0.5–58.2] μg/mL, p = 0.013). The authors concluded that FM is not a good prognostic marker for AMI as it is influenced by common therapies such as PCI and tenecteplase.

Overall, these studies demonstrated increased FM concentrations in patients with AMI. However, the optimal approach could include combining these tests with other laboratory investigations to enhance diagnostic accuracy.

**Fibrin Monomer Concentration and Pregnancy**

Routine pre-natal care does not involve extensive evaluation of coagulation/fibrinoletic markers, unless patients have a history of DVT/PE or thrombophilia. Studies examining the relationship of haemostatic factors to thrombosis during pregnancy focus on establishing baseline concentrations in normal pregnancy, as there are active haemostatic processes occurring throughout pregnancy. In an analysis of thrombophilic markers in normal pregnancies (n = 56), FM, TAT, DD, plasminogen, α2-antiplasmin and tPA were significantly correlated with gestational age (FM correlation coefficient was 0.51; p = 0.002). Additionally, all parameters, except tPA, had average concentrations which were above the upper limit of normal reference ranges (71.1% of FM values were above the upper limit). Specifically, FM and TAT increased with gestational age and were most pronounced in the third trimester. van Wersch and Ubachs2 concluded that coagulation and fibrinolysis markers are elevated throughout normal pregnancy, thus some of these markers, such as FM, could be used to assess hyper-coagulability in patients with high-risk pregnancies, such as thrombosis. Onishi et al.36 compared FM concentrations in 87 normal pregnancies, throughout each term, to 127 non-pregnant females and one woman who developed a post-partum DVT. No significant differences in FM were seen between early and mid-pregnancy. A small significant increase was observed in late pregnancy versus early pregnancy (3.95 vs. 3.35 μg/mL, p < 0.05), yet only 2 of the 39 samples (5.2%) during late pregnancy were greater than the 95% CI value determined by analysis of the non-pregnant females. Further, DD and FDP concentrations were significantly higher in mid- and late pregnancy versus early pregnancy (p < 0.01, each). The patient who developed a post-partum DVT had significantly higher FM (32.4 μg/mL) at the time of diagnosis, with levels returning to baseline after treatment. Since FM remained relatively stable throughout pregnancy compared with other biomarkers, but increased significantly during DVT, FM could be a potential thrombotic marker for uncomplicated pregnancies.

In a study analysing DD, F1+2, TAT and FM concentrations in 101 women with uncomplicated pregnancies, FM concentrations fluctuated throughout pregnancy, showing no correlation with the term of pregnancy as opposed to the other markers.37 Due to this variation, the authors postulated that FM are not a useful marker for hyper-coagulability during pregnancy. Grossman et al.38 investigated the association of maternal and pregnancy factors to DD and FM concentrations in 2,870 pregnant women during the first trimester. On multivariate regression analysis, FM concentrations were influenced by mothers who were overweight, had chronic high blood pressure or had a history of cocaine abuse (p ≤ 0.03, each). Of note, the median FM concentration in this study was 4.3 μg/mL whereas the median DD concentration was 0.3 μg/mL. Since a cut-off of 6.0 μg/mL of FM and 0.5 μg/mL of DD were used to exclude VTE in non-pregnant patients, authors concluded that these concentrations are not applicable to pregnant patients. Furthermore, FM may be used for VTE exclusion in pregnancy, with properly established reference ranges and if maternal characteristics are taken into account.

As noted, assessing hyper-coagulability in pregnancy is complex and involves utilization of coagulation tests with consideration for maternal and foetal factors. Establishing a FM cut-off for early diagnosis of hyper-coagulability in pregnancy is recommended.

**Fibrin Monomer Concentration and Surgery**

Managing thrombosis in surgical patients is extremely important, as shown by the requirement for DVT prophylaxis following surgery. Since many post-op patients are hyper-coagulable, several studies have investigated the relationship of haemostatic factors to DVT or PE development after surgery. Vogel et al.39 evaluated DD, TAT, F1+2 and FM in 129 patients who underwent abdominal surgery. In 12 patients who developed a post-op DVT, FM had the highest sensitivity (91.7%) for diagnosing DVT versus DD, TAT and F1+2 (75.0, 41.7 and 33.3%, respectively). Interestingly, FM and DD were higher in these patients at least 1 day before DVT symptom presentation. This group concluded that FM could be used in early diagnosis of hyper-coagulable states, such as DVT, during the surgical period. Another study investigated the relationship of FM, DD and FDP to the
development of VTE in patients undergoing orthopaedic surgery ($n = 370$), comparing $44$ patients with acute VTE to $241$ patients undergoing total hip arthroplasty and $85$ patients undergoing total knee arthroplasty (TKA). Patients were separated into four groups: without VTE, post-op DVT, sub-clinical DVT and acute VTE. FMs were significantly higher in patients with acute VTE (mean [range]: $13.65 \pm [10.9–19.0]$ vs. post-op DVT $3.80 \pm [2.80–4.88]$), sub-clinical DVT ($4.20 \pm [3.30–5.50]$) and without DVT ($2.90 \pm [2.50–3.80]$ µg/mL). However, FMs were not significantly increased between patients with sub-clinical DVT versus without VTE. ROC analysis of patients with acute VTE and without VTE revealed high FM values ($AUC = 0.9936$, sensitivity $= 97.7\%$, specificity $= 97.8\%$, NPV $= 99.6\%$, PPV $= 96.6\%$, OR $= 1,926$). Further, ROC analysis of patients with sub-clinical DVT and without DVT demonstrated slightly lower FM. They concluded that FM may help diagnose sub-clinical VTE or to predict post-op VTE. Mitani et al. evaluated $50$ patients with TKA and found FM on post-op day $1$ (POD1) significantly correlated with DVT onset ($25.4 \pm 24.0$ µg/mL, $p = 0.001$). In contrast, DD correlated with DVT onset on POD3 ($8.7 \pm 5.9$ µg/mL, $p = 0.043$). Moreover, when DD and FM were analysed together, they enhanced the detection of DVT on POD1 and POD3 ($p < 0.05$). This group concluded that FM may be useful for early DVT diagnosis with improved sensitivity if measured with DD.

Evaluating FM and DD in spinal surgery patients ($n = 72$) with and without VTE development, Yoshioka et al. found patients with VTE had significantly higher FM on POD1 versus those without VTE ($55.9 \pm 17.2$ vs. $11.1 \pm 2.89$ µg/mL, $p < 0.01$). In comparison, DD were higher in patients with VTE versus without VTE on POD7 ($12.5 \pm 2.95$ vs. $4.3 \pm 0.39$ µg/mL, $p < 0.01$). ROC analysis revealed FM was a better predictor of DVT than DD (FM POD1 AUC $= 0.932$; DD POD7 AUC $= 0.858$). They concluded elevated FM on POD1 for spinal surgery patients may suggest future DVT development. Watanabe et al. evaluated haemostatic markers in $56$ patients including $27$ adolescents with idiopathic scoliosis (AIS) who underwent posterior fusion and $29$ patients with lumbosacral spinal canal stenosis (LSSC) who underwent laminectomy. For patients with LSSC, median FM concentrations were significantly increased on POD1 versus pre-operatively ($3.7 \pm 2.9$ µg/mL, $p = 0.01$). For patients with AIS, FM were significantly higher on POD1 and POD3 versus pre-op ($10.0$ and $10.0$ µg/mL, $p = 0.01$, respectively). Overall, FM concentrations were significantly higher on POD1 versus later in the post-op course, indicating FMs have the potential to surpass DD as a marker for spinal surgery post-op thrombosis.

Kochi et al. examined the role of FM in hyper-coagulability for $123$ patients undergoing gastrointestinal surgery. DD on POD7 was used as the main outcome since it was previously demonstrated to be associated with the presence of VTE. Upon analysis of surgical patients who did not receive anti-coagulant therapy after surgery, multivariate analysis revealed plasma FM levels on POD1 were strong predictors for DD elevations on POD7 (OR $= 4.31$, $85\%$ CI: $1.10–18.30$, $p = 0.03$). There was no significant difference in the other clinical risk factors or fibrin-related markers. These findings indicate the potential role of FM in predicting hyper-coagulability and subsequent VTE. Further, the selective administration of anti-coagulant therapy to patients with high FM could be effective for preventing VTE development.

These studies show elevated FM levels throughout the surgical period, with some studies stating FM is superior to DD in predicting DVT development, while others suggest using DD and FM together. Thus, further studies are required to determine FM utility throughout a patient’s surgical stay.

**Discussion**

FM concentrations reflect pro-thrombin activity and have the potential to predict thrombotic events in hyper-coagulable patients earlier than other haemostatic markers. Most often, FMs are compared with DD; however, although DDs have a high sensitivity and NPVs, their specificity is much lower. Following an extensive literature search, there are limited reports investigating the utility of FM in hyper-coagulable patients, including those with DIC, acute ischaemic stroke, AMI, VTE and cancer, as well as those who are pregnant or undergoing surgery. (Table 1).

DIC is a complex physiologic process involving hyper-coagulability and increased fibrinolysis. DDs are utilized as one of the primary laboratory tests to diagnose DIC; however, the aforementioned studies have also shown significantly elevated FM levels in patients with DIC. The difficulty in utilizing haemostatic marker concentrations arises when trying to classify patients based on the DIC severity. Notably, significant increases in FM levels are often more pronounced in overt DIC versus in patients with less severe DIC, or in those who will develop DIC. Still, significant differences in FM concentrations between patients without DIC and pre-DIC/non-overt DIC have been demonstrated, thus FM may be specific enough to distinguish stages of DIC. Limitations in the available literature include the varying aetiologies of DIC in each patient and the co-morbidities they may have which may ultimately enhance thrombosis, and ultimately alter FM values.

Acute ischaemic stroke patients are managed based upon head imaging and cardiac markers, and less likely upon concentrations of haemostatic factors. Due to the emergent presentation of these patients, studies have investigated the relationship of FM to acute stroke only after the acute episode has occurred. Significant increases in FM have been documented in stroke patients who have had a recurrence, as well as in patients with a cardioembolic source. Additionally, medications administered during an acute stroke, such as heparin or rtPA, seem to affect FM concentrations. Future considerations could include prospectively measuring FM levels in patients at higher risk of stroke development, so as to record and compare levels prior to, and after, an event. Other potential ideas include determining whether stroke risk stratification creates groups of patients with different FM levels, how different pharmacologic influences FM levels or how co-morbidities may cause higher ‘baseline’ FM levels. Further studies are required to assess the value of FM concentrations in acute ischaemic stroke patients.

AF patients are known to be hyper-coagulable; however, evaluation of haemostatic biomarkers is not considered in...
current practices. In the few studies that are available, some results have shown that FM do not differ between patients with and without AF, and FM are not a good predictor of future thromboembolic events, while others suggest FM could be related to thrombosis, yet it is unclear whether they could help with risk stratification. These controversial findings are due to numerous variables that should be considered during FM evaluation, such as prior history of a thromboembolic event, anti-coagulation prophylactic therapy and recent invasive procedures.

AMI patients are evaluated using electrocardiographies and cardiac troponins, without routine assessment of FM or DD levels. Similar to acute ischaemic stroke, studies looking at FM levels in these patients focused on concentrations following the event. Results have shown increased FM in the first 24 hours post-MI, as well as enhanced detection of AMI when used simultaneously with cardiac troponins. Thus, rather than using FM to predict AMI, FM could be used to monitor patients after clinical presentation to assess treatment response. As mentioned, literature with inquiry into DD levels. Similar to acute ischaemic stroke, studies looking at how FM levels change in DVT patients from initial presentation, to after therapy, and to the day (or days) after the event would be beneficial, as well as measuring levels more often throughout an acute event to see if there are changes hourly, for example. Additionally, research could be conducted on how patients with a history of MI may have different FM levels compared with the normal population or how patients with cardiovascular risk factors are likely to be on specific medications affecting coagulation and likely FM levels.

VTE are frequently encountered in the acute hospital setting with DD concentrations helping guide treatment. However, the role of FM levels in this setting is not well understood. From the abovementioned literature, diagnosing DVT appears optimal when both FM and DD concentrations are used together versus independently. There are less data for FM concentrations in patients with PE, although some results have demonstrated that FM can help exclude PE in patients with chest pain. It is still unclear whether including FM in routine testing for DVT or PE improves patient outcome. Analysis of other factors affecting FM is needed, including further studies with PE patients, studies looking at how FM levels change in DVT patients from initial presentation, to after therapy, and to the day (or days) after admission.

Hyper-coagulability is common in cancer patients, yet there has been little investigation into their FM levels. Higher FM concentrations were reported in patients with active malignancy and in those who died from their disease. Further, increased FM concentrations were associated with increased platelet binding, which were hypothesized to propagate metastasis. Cancer patients often have multiple co-morbidities, which may enhance hyper-coagulability and the difficulty in interpreting the significance of haemostatic parameters. Further studies are also required to assess the FM value in cancer patients. These studies could include looking at the level of FM/haemostatic markers in different cancer types and in different age groups, in addition to the type of treatment given (chemotherapy/radiation) or the length of remission.

Numerous physiologic changes occur during pregnancy and these variations are reflected in FM concentrations. Some groups have reported no correlation of FM concentration to the stage of pregnancy, whereas others have reported increased concentrations in advanced pregnancies or in patients with different maternal characteristics. Onishi et al. reported no difference in FM concentrations between non-pregnant females and pregnant individuals. These contradictory results confirm the difficulty in assessing hyper-coagulability in pregnancy and in determining a cut-off value for FM levels, which should be considered in future studies. Research could explore FM levels after pregnancy to see if giving birth decreases FM levels immediately or if it takes some time. Perhaps mothers with elevated FM levels after birth are at higher risk of future thrombotic events. Other interesting areas could involve comparing FM levels during pregnancy and then while the mother is having natural birth versus C-section, or measuring FM levels in higher risk pregnancies, which could potentially help identify mothers who could be more at risk for perinatal complications.

Understanding the role of FM in surgical patients is essential for the investigation of post-op DVT development. Literature has shown that FM can be used to detect hyper-coagulable states during the surgical period, for example, increased FM on POD1 was associated with DVT development. Similar to VTE, these studies have also shown using FM and DD together is more accurate for diagnosing early post-op DVTs. More research is needed comparing FM levels prior to, during and after surgery, as well as how DVT prophylaxis during the surgical period (whether anti-coagulants or compression stockings) could affect FM. Other ideas include comparing FM post-operatively in patients who lost blood or received blood products during the procedure, as these patients may be at higher risk of thrombosis.

In summary, utilizing FM to assess hyper-coagulable patients seems promising; however, there are limitations which require further investigation before a true advantage for this marker can be established. Each research team has used a different cut-off value for FM level to be considered ‘elevated’, thus without a universal cut-off value the statistical results cannot be easily compared. In addition, much of the literature has assessed FM after the initial thrombotic event, such as AMI or acute ischaemic stroke, therefore it is unknown what FM concentrations are leading up to the acute event and how they relate to levels after the event. The cut-off value is likely going to vary depending upon the cause of thrombosis, when FM levels are measured throughout a hyper-coagulable event, and if/when anti-coagulant medications are given, elements which may only be deciphered with more research.

Authors’ Contributions
M.A.R.: Developing the concept of the review, editing drafts of the manuscript and revising for proper clinical content. P.R.: Revising and editing final drafts of the manuscript. T.M.: Revising and editing final drafts of the manuscript. P.D.B.: Performing the literature review, writing and editing drafts of the manuscript.
Conflict of Interest
M.A.R. provides external consulting and professional services to Diagnostica Stago; P.R. and T.M. are salaried employees of Diagnostica Stago, Inc. P.D.B.: None.

References
1 Lee MS, Kong J. Heparin: physiology, pharmacology, and clinical application. Rev Cardiovasc Med 2015;16(03):189–199
9 Selim TE, Ghoneim HR, Khashaba MT, Rakha SA. Plasma soluble fibrin monomer complex is a useful predictor of disseminated intravascular coagulation in neonatal sepsis. Haematologica 2005;90(03):419–421


45 Samuelson Bannow BT. Capsule commentary on Rivera-Caravaca et al., soluble fibrin monomer complex and prediction of cardiovascular events in atrial fibrillation: the observational Murcia Atrial Fibrillation Project. J Gen Intern Med 2018;33(06):945